© 2020 MJH Life Sciences, Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Multiple Myeloma
FDA Accepts sNDA for Selinexor as Treatment of Patients With Multiple Myeloma
July 20, 2020
The FDA has accepted the supplemental New Drug Application seeking approval of selinexor as treatment of patients with multiple myeloma following at least 1 prior line of therapy.
FDA ODAC Votes in Favor of Belantamab Mafodotin Approval for Relapsed or Refractory Myeloma
July 14, 2020
“We are pleased the committee recognised the potential for belantamab mafodotin to help patients who have relapsed or refractory multiple myeloma, an incurable disease with limited treatment options."
Multidrug Combinations and CAR T-Cell Therapies for Heavily Pretreated Multiple Myeloma Shine at ASCO
July 07, 2020
Breakthrough data for systemic therapies in the treatment of various hematologic malignancies impressed attendees at the American Society of Clinical Oncology 2020 Virtual Scientific Program.
Evaluating Response Rates With CC-92480 Combination in Multiple Myeloma
July 07, 2020
Paul G. Richardson, MD, discusses the response rates observed in the first-in-human phase 1 trial of CC-92480 and dexamethasone in patients with relapsed/refractory multiple myeloma.
Vescio Debates Quadruplet Versus Triplet Therapy in Newly Diagnosed Multiple Myeloma
July 03, 2020
Robert A. Vescio, MD, discussed two treatment options for a 51-year-old male patient with newly diagnosed multiple myeloma.
Isatuximab Triplet Regimen Improves PFS Compared With Doublet in Relapsed Myeloma
June 30, 2020
In an interview with Targeted Oncology, Phillipe Moreau, MD, discussed the findings from the IKEMA trial and what these date mean for the treatment landscape of relapsed multiple myeloma.
SWOG 1211 Shows Longer Efficacy Than Historical Data for Multiple Myeloma
June 26, 2020
Saad Z. Usmani, MD, discusses the phase 2 SWOG 1211 trial investigating bortezomib, lenalidomide, and dexamethasone with or without elotuzumab for patients with newly diagnosed, high-risk multiple myeloma.
FDA’s ODAC to Review Belantamab Mafodotin BLA for R/R Multiple Myeloma
June 22, 2020
The FDA has announced plans to convene a meeting of the Oncologic Drugs Advisory Committee to review the Biologic License Application for belantamab mafodotin as treated of patients with relapsed or refractory multiple myeloma.
Study Identifies Independent Predictors of Smoldering Multiple Myeloma Progression
June 09, 2020
“We found that the genomic alterations with smoldering multiple myeloma are essentially the same as full-fledged myeloma. This suggests that by the time smoldering multiple myeloma is diagnosed, most of the molecular abnormalities found in myeloma have already occurred.”
JNJ-4528 Remains Under Evaluation for Relapsed/Refractory Multiple Myeloma
June 03, 2020
Jesus Berdeja, MD, discusses the next steps for the chimeric antigen receptor T-cell therapy JNJ-4528 following the data from the phase 1b portion of the CARTITUDE-1 trial in patients with relapsed/refractory multiple myeloma.